Targeting castration-resistant prostate cancer with a novel ROR
Jianwei ZHENG; Junfeng WANG; Qian WANG; Hongye ZOU; Hong WANG; Zhenhua ZHANG; Jianghe CHEN; Qianqian WANG; Panxia WANG; Yueshan ZHAO; Jing LU; Xiaolei ZHANG; Songtao XIANG; Haibin WANG; Jinping LEI; Hong-Wu CHEN; Peiqing LIU; Yonghong LIU; Fanghai HAN; Junjian WANG.
Acta Pharmaceutica Sinica B
; (6): 2313-2322, 2020.
Artículo
en Inglés
| WPRIM | ID: wpr-881113
Prostate cancer (PCa) patients who progress to metastatic castration-resistant PCa (mCRPC) mostly have poor outcomes due to the lack of effective therapies. Our recent study established the orphan nuclear receptor ROR
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados